Statin use and exacerbations in individuals with chronic obstructive pulmonary disease
Authors:
Open Access
Abstract
Background We tested the hypothesis that statin use in individuals with COPD is associated with a reduced risk of exacerbations. Methods We identified 5794 individuals with COPD and a measurement of C reactive protein (CRP) in the Copenhagen General Population Study (2003–2008). During 3 years of follow-up we recorded exacerbations with hospital admissions or oral corticosteroid treatment. In a nested case-control design, matching on age, gender, smoking, COPD severity and comorbidity, we estimated the association between statin use and exacerbations. In addition, we examined the association between statin use and high CRP (>3 mg/L), and the association between high CRP and exacerbations during follow-up. Results Statin use was associated with reduced odds of exacerbations in crude analysis, OR=0.68 (95% CI 0.51 to 0.91, p=0.01), as well as in multivariable conditional logistic regression analysis, OR=0.67 (0.48 to 0.92, p=0.01). However, in the subgroup with the most severe COPD and without cardiovascular comorbidity, we observed a null association between statin use and exacerbations, OR=1.1 (0.5 to 2.1, p=0.83). Furthermore, statin use was associated with reduced odds of a high CRP, OR=0.69 (0.56 to 0.85, pConclusions Statin use was associated with reduced odds of exacerbations in individuals with COPD from the general population, although this was not apparent in those with the most severe COPD without cardiovascular comorbidity. Statins may thus only associate with reduced risk of exacerbations in patients with COPD with coexisting cardiovascular disease.Keywords
This publication has 39 references indexed in Scilit:
- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2013
- Pleiotropic effects of pitavastatinBritish Journal of Clinical Pharmacology, 2012
- Susceptibility to Exacerbation in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2010
- Systemic inflammation and comorbidity in COPD: a result of 'overspill' of inflammatory mediators from the lungs? Review of the evidenceThorax, 2010
- Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: a review of the evidencePostgraduate Medical Journal, 2009
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinNew England Journal of Medicine, 2008
- Pleiotropic effects of statin therapy: molecular mechanisms and clinical resultsTrends in Molecular Medicine, 2008
- Chronic obstructive pulmonary disease: current burden and future projectionsEuropean Respiratory Journal, 2006
- Burden and clinical features of chronic obstructive pulmonary disease (COPD)The Lancet, 2004
- Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysisThorax, 2004